Elena Ridloff
Known title: CFO & Head of Corp. Dev.CIK: 0001772518
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Raymond James initiates coverage on Kymera with Outperform rating. Raymond James has started covering Kymera Therapeutics, assigning an Outperform rating and a price target of $140. This new analyst note adds to the current consensus, which has an average target of $139.35 from 23 analysts. Recent discussions also question whether the company's pipeline is over-hyped or developing into a major therapeutic success.
Transaction History
| SION | ▲ Buy | Grant | 47,269 | $0 | 9/17/2026 | View on chart |
| SION | ▲ Buy | Grant | 47,268 | $0 | 9/17/2026 | View on chart |
| KYMR | ▲ Buy | Option Exercise | 3,000 | $94K | 5/11/2026 | View on chart |
| KYMR | ▼ Sell | Open Market | 3,000 | $261K | 5/11/2026 | View on chart |
| KYMR | ▲ Buy | Option Exercise | 4,600 | $65K | 4/1/2026 | View on chart |
| KYMR | ▼ Sell | Open Market | 3,400 | $290K | 4/1/2026 | View on chart |
| KYMR | ▼ Sell | Open Market | 1,200 | $103K | 4/1/2026 | View on chart |
| KYMR | ▲ Buy | Option Exercise | 7,400 | $105K | 3/31/2026 | View on chart |
| KYMR | ▼ Sell | Open Market | 7,400 | $632K | 3/31/2026 | View on chart |
| SION | ▼ Sell | Open Market | 8,836 | $222K | 9/2/2025 | View on chart |
| SION | ▼ Sell | Open Market | 748 | $19K | 8/29/2025 | View on chart |
| SION | ▼ Sell | Open Market | 16,098 | $418K | 8/28/2025 | View on chart |
| SION | ▼ Sell | Open Market | 3,618 | $91K | 8/27/2025 | View on chart |
| SION | ▼ Sell | Open Market | 3,700 | $93K | 8/26/2025 | View on chart |
| SION | ▼ Sell | Open Market | 17,500 | $397K | 8/20/2025 | View on chart |
| SION | ▼ Sell | Open Market | 34,500 | $727K | 8/19/2025 | View on chart |
| KYMR | ▼ Sell | Open Market | 4,500 | $225K | 6/11/2025 | View on chart |
| KYMR | ▲ Buy | Option Exercise | 4,500 | $91K | 6/11/2025 | View on chart |
| KYMR | ▲ Buy | Option Exercise | 12,000 | $332K | 6/3/2025 | View on chart |
| KYMR | ▼ Sell | Open Market | 7,200 | $328K | 6/3/2025 | View on chart |
| KYMR | ▼ Sell | Open Market | 4,800 | $226K | 6/3/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Sionna Shares Fall 37.6% Over 4 Weeks, Trend Reversal Possible
Sionna Therapeutics shares fell 37.6% over the past four weeks. The drop has pushed the stock into a low RSI zone of 23.4, suggesting it may be oversold. The price is near a key support level at $5.71, which has been tested 20 times. Analysts see a potential trend reversal, but the stock remains far below its 52‑week high of $54.97.
Sionna Shares Fall 37.6% Over 4 Weeks, Trend Reversal Possible. Sionna Therapeutics shares fell 37.6% over the past four weeks. The drop has pushed the stock into a low RSI zone of 23.4, suggesting it may be oversold. The price is near a key support level at $5.71, which has been tested 20 times. Analysts see a potential trend reversal, but the stock remains far below its 52‑week high of $54.97.